Introduction: The survival rate of patients with Borrmann type 4 advanced gastric cancer is extremely poor in comparison to patients with gastric cancers of other histological types. An optimal chemotherapeutic regime...Introduction: The survival rate of patients with Borrmann type 4 advanced gastric cancer is extremely poor in comparison to patients with gastric cancers of other histological types. An optimal chemotherapeutic regimen has yet to be determined. Patients and Methods: We retrospectively examined the outcome of patients who were treated for Borrmann type 4 advanced gastric cancer from July 2011 and June 2015. Results: The data from 42 cases were collected for this study. Of the 42 cases, 13 cases (31.0%) were locally advanced and 29 cases (69.0%) were metastatic advanced. Median Overall Survival (OS) for locally advanced cancer was 29.6 months and for metastatic advanced cancer was 11.5 months. The presence or absence of peritoneal metastases did not affect survival (8.9 and 11.5 months, respectively;p = 0.831). In the 23 patients who received chemotherapy, S-1 plus cisplatin was prescribed as first-line treatment in 16 cases (69.5%). Other treatment regimens included capecitabine plus cisplatin and S-1 plus oxaliplatinin one each (4.3%), S-1 monotherapy in two (8.6%), and capecitabine monotherapy, paclitaxel, and docetaxel in one each (4.3%). We found no median OS difference between S-1 plus cisplatin and other treatments (20.7 and 19.3 months;p = 0.094). Conclusion: We found that S-1 plus cisplatin treatment does not improve OS in patients with Borrmann type 4 advanced gastric cancer compared with other chemotherapeutic regimens.展开更多
文摘Introduction: The survival rate of patients with Borrmann type 4 advanced gastric cancer is extremely poor in comparison to patients with gastric cancers of other histological types. An optimal chemotherapeutic regimen has yet to be determined. Patients and Methods: We retrospectively examined the outcome of patients who were treated for Borrmann type 4 advanced gastric cancer from July 2011 and June 2015. Results: The data from 42 cases were collected for this study. Of the 42 cases, 13 cases (31.0%) were locally advanced and 29 cases (69.0%) were metastatic advanced. Median Overall Survival (OS) for locally advanced cancer was 29.6 months and for metastatic advanced cancer was 11.5 months. The presence or absence of peritoneal metastases did not affect survival (8.9 and 11.5 months, respectively;p = 0.831). In the 23 patients who received chemotherapy, S-1 plus cisplatin was prescribed as first-line treatment in 16 cases (69.5%). Other treatment regimens included capecitabine plus cisplatin and S-1 plus oxaliplatinin one each (4.3%), S-1 monotherapy in two (8.6%), and capecitabine monotherapy, paclitaxel, and docetaxel in one each (4.3%). We found no median OS difference between S-1 plus cisplatin and other treatments (20.7 and 19.3 months;p = 0.094). Conclusion: We found that S-1 plus cisplatin treatment does not improve OS in patients with Borrmann type 4 advanced gastric cancer compared with other chemotherapeutic regimens.
